A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3229-3236

  Kusunoki, Natsuko ^a   Ito, Takumi ^b   Sakurai, Nobuyuki ^b   Handa, Hiroshi ^b   Kawai, Shinichi ^a,c  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Celecoxib; Colon adenocarcinoma; Cyclooxygenase; HT 29 cell; Prostaglandin E2; TT101

Indexed keywords

2 (4 IODOPHENYL) 3 (4 NITROPHENYL) 5 (2,4 DISULFOPHENYL) 2H TETRAZOLIUM MONOSODIUM; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BROXURIDINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA FRAGMENT; N (2 AMINOETHYL) 4 [5 (4 TOLYL) 3 (TRIFLUOROMETHYL) 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; PROSTAGLANDIN E2; ROFECOXIB; SODIUM DERIVATIVE; TETRAZOLIUM; TT 101; TT 201; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ADENOCARCINOMA; APOPTOSIS; CASPASES; CELL PROLIFERATION; COLONIC NEOPLASMS; DINOPROSTONE; ENZYME ACTIVATION; HT29 CELLS; HUMANS; PYRAZOLES; SULFONAMIDES;

EID: 33750696296     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Xie WL, Chipman JG, Robertson DL, Erikson RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88(7): 2692-2696, 1991.
2. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266(20): 12866-12872, 1991.
3. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26): 1946-1952, 2000.
4. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531(2): 278-284, 2002.
5. Xiong HQ: Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol Suppl 1: S69-77, 2004.
6. Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol 31(2 Suppl 7): 45-52, 2004.
7. Arun B and Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31(2 Suppl 7): 22-29, 2004.
8. Kismet K, Akay MT, Abbasoglu O and Ercan A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 28(2): 127-142, 2004.
9. Sinicrope FA and Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23(1-2): 63-75, 2004.
10. Myers C, Koki A, Pamukcu R, Wechter W and Padley RJ: Proapoptotic anti-inflammatory drugs. Urology 57(4 Suppl 1): 73-76, 2001.
11. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD and Stephens LC: Familial Adenomatous Polyposis Study Group: Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6): 920-927, 2004.
12. McAdam BF, Catella-Lawson F, Mardini JA, Kapoor S, Lawson JA and FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96(1): 272-277, 1999.
13. Kusunoki N, Ito T, Sakurai N, Suguro T, Handa H and Kawai S: A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J Pharmacol Exp Ther 314(2): 796-803, 2005.
14. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40(9): 1347-1365, 1997.
15. International Patent Publication WO95/00501.
16. Kato M, Nishida S, Kitasato H, Sakata N and Kawai S: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 53(12): 1679-1685, 2001.
17. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H and Kawai S: Membrane-associated prostaglandin E synthase-1 is up-regulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 6(4): R355-365, 2004.
18. Smith ML, Hawcroft G and Hull MA: The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36(5): 664-674, 2000.
19. Baier A, Meineckel I, Gay S and Pap T: Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 15(3): 274-279, 2003.
20. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK and Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64(12): 4309-4318, 2004.